The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 801–1,000 of 1,264
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia
García‐Cañaveras, J. C., Lancho, O., Ducker, G. S., Ghergurovich, J. M., Xu, X., da Silva-Diz, V., Minuzzo, S. A., Indraccolo, S., Kim, H., Herranz, D., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0845-6 · Cited by 140
Jl, L., Chen, F.-F., Lung, J., Lo, C.-H., Lee, F., Lu, Y.-C., & Hung, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.355 · Cited by 139
Zeb2: A multifunctional regulator of nervous system development
Hegarty, S. V., Sullivan, A. M., & O’Keeffe, G. W. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.001 · Cited by 138
Zhang, J., Yao, Y., Li, B., Yang, Q., Zhang, P.-Y., & Wang, H.-T. (2015) · Scientific Reports · doi:10.1038/srep09800 · Cited by 138
Doll, J. A., Reiher, F., Crawford, S. E., Pins, M. R., Campbell, S. C., & Bouck, N. (2001) · The Prostate · doi:10.1002/pros.10025 · Cited by 138
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie‐Hurder, A., Digumarthy, S. R., Gainor, J. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0383 · Cited by 138
Small-molecule Bax agonists for cancer therapy
Xin, M., Li, R., Xie, M., Park, D., Owonikoko, T. K., Sica, G., Corsino, P. E., Zhou, J., Ding, C., White, M. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5935 · Cited by 137
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Freeman‐Cook, K. D., Hoffman, R. L., Behenna, D. C., Boras, B. W., Carelli, J. D., Diehl, W. C., Ferre, R. A., He, Y.-A., Hui, A., Huang, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00159 · Cited by 136
Oh, S. Y., Kim, S., Keam, B., Kim, T. M., Kim, D., & Heo, D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99311-y · Cited by 136
Angevin, E., Lopez-Martin, J. A., Lin, C., Gschwend, J. E., Harzstark, A. L., Castellano, D., Soria, J., Sen, P., Chang, J. E., Shi, M. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2885 · Cited by 135
Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium
Szlosarek, P. W., Grimshaw, M. J., Kulbe, H., Wilson, J. L., Wilbanks, G. D., Burke, F., & Balkwill, F. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0303 · Cited by 135
Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Pan-cancer molecular analysis of the RB tumor suppressor pathway
Knudsen, E. S., Nambiar, R., Rosario, S. R., Smiraglia, D. J., Goodrich, D. W., & Witkiewicz, A. K. (2020) · Communications Biology · doi:10.1038/s42003-020-0873-9 · Cited by 135
Veatch, A. L., Carson, L. F., & Ramakrishnan, S. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580315 · Cited by 134
Hu, L., Ru, K., Zhang, L., Huang, Y.-T., Zhu, X., Liu, H., Zetterberg, A., Cheng, T., & Miao, W. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-3 · Cited by 134
Middleton, M. R., Dean, E. J., Evans, T. R. J., Shapiro, G. I., Pollard, J. R., Hendriks, B. S., Falk, M., Díaz-Padilla, I., & Plummer, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01405-x · Cited by 134
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Song, K. W., Edgar, K. A., Hanan, E. J., Hafner, M. A., Oeh, J., Merchant, M. A., Sampath, D., Nannini, M. A., Hong, R., Phu, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0072 · Cited by 134
Colbert, L. E., Fisher, S. B., Hardy, C. W., Hall, W. A., Saka, B., Shelton, J. W., Petrova, A. V., Warren, M. D., Pantazides, B. G., Gandhi, K., et al. (2013) · Cancer · doi:10.1002/cncr.28144 · Cited by 133
Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
Mashreghi, M., Azarpara, H., Bazaz, M. R., Jafari, A., Masoudifar, A., Mirzaei, H., & Jaafari, M. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26049 · Cited by 133
Clinical significance of tumor markers and an emerging perspective on colorectal cancer
Yamashita, K., & Watanabe, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01022.x · Cited by 132
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Roberts, W. G., Whalen, P. M., Söderström, E., Moraski, G. C., Lyssikatos, J. P., Wang, H. F., Cooper, B. A., Baker, D. A., Savage, D. M., Dalvie, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.957.65.3 · Cited by 132
Circulating Biomarkers in Breast Cancer
Seale, K. N., & Tkaczuk, K. H. R. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.006 · Cited by 132
Biological Roles of Alpha-Fetoprotein During Pregnancy and Perinatal Development
Mizejewski, G. J. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900602 · Cited by 131
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-020-01464-z · Cited by 131
Salamero, O., Montesinos, P., Willekens, C., Pérez‐Simón, J. A., Pigneux, A., Récher, C., Popat, R., Carpio, C. D. C., Molinero, C., Mascaró, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03250 · Cited by 130
Fusco, N., Malapelle, U., Fassan, M., Marchiò, C., Buglioni, S., Zupo, S., Criscitiello, C., Vigneri, P. G., Tos, A. P. D., Maiorano, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644737 · Cited by 130
P120 and E-cadherin: Double-edged swords in tumor metastasis
Venhuizen, J., Jacobs, F. J. C., Span, P. N., & Zegers, M. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.020 · Cited by 129
Yang, A., Liu, J., Lei, H., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.07.034 · Cited by 128
Zhu, F., He, L., Peng, K., Liu, Y., & Xiong, J. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s52805 · Cited by 128
Structure and Function of Alpha-Fetoprotein
Tomasi, T. B. (1977) · Annual Review of Medicine · doi:10.1146/annurev.me.28.020177.002321 · Cited by 128
Aptasensors as a new sensing technology developed for the detection of MUC1 mucin: A review
Yousefi, M., Dehghani, S., Nosrati, R., Zare, H., Evazalipour, M., Mosafer, J., Tehrani, B. S., Pasdar, A., Mokhtarzadeh, A., & Ramezani, M. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.01.015 · Cited by 128
A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?
Vandenbroucke, R. E., Dejonckheere, E., & Libert, C. (2011) · European Respiratory Journal · doi:10.1183/09031936.00027411 · Cited by 127
Targeting the fibroblast growth factor receptor family in cancer
Hallinan, N., Finn, S. P., Cuffe, S. D., Rafee, S., O'Byrne, K. J., & Gately, K. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.015 · Cited by 127
Bcl-XL protects cancer cells from p53-mediated apoptosis.
Schott, A., Ij, A., Núñez, G., & Clarke, M. F. (1995) · PubMed · Cited by 127
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Müller, T., Braun, M., Dietrich, D., Aktekin, S., Höft, S., Kristiansen, G., Göke, F., Schröck, A., Brägelmann, J., Held, S. A. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17547 · Cited by 127
Casara, P., Davidson, J. E. P., Clapéron, A., Toumelin-Braizat, G. L., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Diguarher, T. L., Starck, J.-B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24744 · Cited by 126
Young, A., Oldford, C., & Mailloux, R. J. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101339 · Cited by 126
Zhao, H., Yang, M., Zhao, J., Wang, J., Zhang, Y., & Zhang, Q. (2013) · Medical Oncology · doi:10.1007/s12032-013-0475-1 · Cited by 125
Self-citationInflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma
Dunn, J. H., Ellis, L. Z., & Fujita, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.001 · Cited by 124
A Novel Signaling Axis of Matriptase/PDGF-D/β-PDGFR in Human Prostate Cancer
Ustach, C. V., Huang, W., Conley‐LaComb, M. K., Lin, C., Che, M., Abrams, J., & Kim, H.-R. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0511 · Cited by 124
Pal, M., Muinao, T., Boruah, H. P. D., & Mahindroo, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112488 · Cited by 124
Xuan, Y., & Hu, X. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.029 · Cited by 123
Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease
Noguchi, M., Hiwatashi, N., Liu, Z., & Toyota, T. (1998) · Gut · doi:10.1136/gut.43.2.203 · Cited by 123
Radioimmunoassay: Review of basic principles
Goldsmith, S. J. (1975) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(75)80028-6 · Cited by 123
Staurosporine Induces Necroptotic Cell Death under Caspase-Compromised Conditions in U937 Cells
Dunai, Z. A., Imre, G., Barna, G., Korcsmáros, T., Peták, I., Bauer, P. I., & Mihalik, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041945 · Cited by 123
Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
Wang, H., Wang, L., Zhang, Y., Wang, J., Deng, Y., & Lin, D. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0280-y · Cited by 123
Self-citationTargeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 123
Matrix metalloproteinases and their clinical relevance in urinary bladder cancer
Szarvas, T., Dorp, F. V., Ergün, S., & Rubben, H. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.44 · Cited by 122
N-cadherin as a therapeutic target in cancer
Mariotti, A., Perotti, A., Sessa, C., & Rüegg, C. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.451 · Cited by 122
Targeting ATR in patients with cancer
Ngoi, N. Y. L., Pilie, P. G., McGrail, D. J., Zimmermann, M., Schlacher, K., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00863-5 · Cited by 122
Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population
Chen, X., Zhang, W., Yang, K., Wang, L., Liu, J., Wang, L., Hu, J.-K., Zhang, B., Chen, Z., Chen, J., et al. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1774-x · Cited by 121
Goldberg, L., & Kloog, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1878 · Cited by 121
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer
Xu, Y., Zhang, P., Zhang, K., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188634 · Cited by 121
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7117 · Cited by 120
Radioimmunoassay, enzyme and non-enzyme-based immunoassays
Grange, R. D., Thompson, J. P., & Lambert, D. G. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aet293 · Cited by 120
Avilés‐Jiménez, F., Güitrón, A., Segura-López, F. K., Méndez-Tenorio, A., Iwai, S., Hernández-Guerrero, A., & Torres, J. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.008 · Cited by 120
Bcl-XL: A multifunctional anti-apoptotic protein
Li, M., Wang, D., He, J., Chen, L., & Li, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104547 · Cited by 120
CDK inhibitors from past to present: A new wave of cancer therapy
Jameel, M., Bhadresha, K. P., & Kwok, H. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.006 · Cited by 120
Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos, P. I., & Solit, D. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001948 · Cited by 119
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso‐Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 119
The Role of Beclin 1-Dependent Autophagy in Cancer
Vega-Rubín-de-Celis, S. (2019) · Biology · doi:10.3390/biology9010004 · Cited by 119
The structure, metabolism and function of the carcinoembryonic antigen gene family
Thomas, P., TOTH, C. A., Saini, K. S., Jessup, J. M., & Steele, G. D. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90003-j · Cited by 117
Key roles of necroptotic factors in promoting tumor growth
Liu, X., Zhou, M., Mei, L., Ruan, J., Hu, Q., Peng, J., Su, H., Liao, H., Liu, S., Liu, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7924 · Cited by 117
Development and safety of PI3K inhibitors in cancer
Yu, M., Chen, J., Xu, Z., Yang, B., He, Q., Luo, P., Yan, H., & Yang, X. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03440-4 · Cited by 117
Self-citationRolland, P., Madjd, Z., Durrant, L. G., Ellis, I. O., Layfield, R., & Spendlove, I. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01312 · Cited by 115
Targeting the Apoptosome for Cancer Therapy
Ledgerwood, E. C., & Morison, I. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1172 · Cited by 114
Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
Moradi, A., Srinivasan, S., Clements, J., & Batra, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09815-3 · Cited by 114
Small molecule probes for targeting autophagy
Whitmarsh‐Everiss, T., & Laraia, L. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00768-9 · Cited by 114
Xie, X., Padrón, D., Liao, X., Wang, J., Roth, M. G., & Brabander, J. K. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313796200 · Cited by 113
P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer
Bae, J. Y., Lee, S.-W., Shin, Y., Lee, J.-H., Jahng, J. W., & Park, K. (2017) · Oncotarget · doi:10.18632/oncotarget.16903 · Cited by 113
Plummer, R., Vidal, L., Griffin, M., Lesley, M., Bono, J. S. D., Coulthard, S. A., Sludden, J., Siu, L. L., Chen, E. X., Oza, A. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2859 · Cited by 112
Goodall, M. L., Wang, T., Martin, K. R., Kortus, M. G., Kauffman, A. L., Trent, J. M., Gately, S. T., & MacKeigan, J. P. (2014) · Autophagy · doi:10.4161/auto.28594 · Cited by 112
FGFR Signaling as a Target for Lung Cancer Therapy
Desai, A., & Adjei, A. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.08.003 · Cited by 112
Paoletti, C., Cani, A. K., Larios, J. M., Hovelson, D. H., Aung, K., Darga, E. P., Cannell, E. M., Baratta, P. J., Liu, C., Chu, D. T. W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2686 · Cited by 112
Liu, L., Zeng, W., Wortinger, M. A., Yan, S., Cornwell, P. D., Peek, V. L., Stephens, J. R., Tetreault, J. W., Xia, J., Manro, J. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0543 · Cited by 111
Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC)
Ferrigno, D., Buccheri, G., & Giordano, C. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00232-0 · Cited by 111
Update on the types and usage of liquid biopsies in the clinical setting: a systematic review
Arneth, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4433-3 · Cited by 111
Choi, J., Jung, W., & Koo, J. S. (2012) · Histopathology · doi:10.1111/his.12002 · Cited by 110
(2003) · PubMed · Cited by 110
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Deisseroth, A., Ko, C., Nie, L., Zirkelbach, J. F., Zhao, L. Y., Bullock, J. M., Mehrotra, N., Valle, P. D., Saber, H., Sheth, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1678 · Cited by 110
Targeting PI3K signaling in cancer: Challenges and advances
Santis, M. C. D., Gulluni, F., Campa, C. C., Martini, M., & Hirsch, E. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.03.003 · Cited by 110
The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets
Dabravolski, S. A., Khotina, V. A., Omelchenko, A. V., Kalmykov, V. A., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020931 · Cited by 110
Li, V. D., Li, K. H. L., & Li, J. T. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2817-z · Cited by 109
Zhu, R., Li, L., Nguyen, B., Seo, J., Wu, M. H., Seale, T. S., Levis, M. J., Duffield, A. S., Hu, Y., & Small, D. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00578-4 · Cited by 109
Pugsley, H. R. (2017) · Journal of Visualized Experiments · doi:10.3791/55637 · Cited by 108
Kumar, M., Allison, D. F., Baranova, N. N., Wamsley, J. J., Katz, A. J., Bekiranov, S., Jones, D. R., & Mayo, M. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068597 · Cited by 107
A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
Brooks, K. M., Oakes, V., Edwards, B., Ranall, M. V., Leo, P., Pavey, S. J., Pinder, A., Beamish, H., Mukhopadhyay, P., Lambie, D., et al. (2012) · Oncogene · doi:10.1038/onc.2012.72 · Cited by 107
BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.
Gatto, C., Rieppi, M., Borsotti, P., Innocenti, S., Ceruti, R., Drudis, T., Scanziani, E., Casazza, A. M., Taraboletti, G., & Giavazzi, R. (1999) · PubMed · Cited by 107
Piérard, G. E., Arrese, J. E., & Piérard-Franchimont, C. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.2.287 · Cited by 107
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Therapeutic exploitation of necroptosis for cancer therapy
Fulda, S. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.07.002 · Cited by 106
Microarray analysis of promoter methylation in lung cancers
Fukasawa, M., Kimura, M., Morita, S., Matsubara, K., Yamanaka, S., Endo, C., Sakurada, A., Sato, M., Kondo, T., Horii, A., et al. (2006) · Journal of Human Genetics · doi:10.1007/s10038-005-0355-4 · Cited by 106
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01347-3 · Cited by 106
Aberrant Expression of Interleukin-1β and Inflammasome Activation in Human Malignant Gliomas
Tarassishin, L., Casper, D., & Lee, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103432 · Cited by 105
Diversity within the pRb pathway: is there a code of conduct?
Munro, S., Carr, S. M., & Thangue, N. B. L. (2012) · Oncogene · doi:10.1038/onc.2011.603 · Cited by 105
CRISPR/Cas-Based In Vitro Diagnostic Platforms for Cancer Biomarker Detection
Gong, S., Zhang, S., Lü, F., Pan, W., Li, N., & Tang, B. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02533 · Cited by 105
Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation
Owonikoko, T. K., & Khuri, F. R. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e395 · Cited by 104
Matrix Metalloproteinases in Non-Neoplastic Disorders
Tokito, A., & Jougasaki, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071178 · Cited by 104
Charakorn, C., Thadanipon, K., Chaijindaratana, S., Rattanasiri, S., Numthavaj, P., & Thakkinstian, A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.03.056 · Cited by 104
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155523 · Cited by 103
Parola, C., Neumeier, D., & Reddy, S. T. (2017) · Immunology · doi:10.1111/imm.12838 · Cited by 103
Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology
Muinelo‐Romay, L., Casas‐Arozamena, C., & Abal, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082311 · Cited by 101
Kang, C. (2021) · Drugs · doi:10.1007/s40265-021-01567-1 · Cited by 101
Cancer vaccination with telomerase peptide GV1001
Kyte, J. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902897631 · Cited by 100
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
Kim, K. H., & Kim, H. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.17 · Cited by 99
Liu, Z., Zheng, M., Li, Y., Fan, X., Wang, J., Li, Z., Yang, H., Yu, J., Cui, J., Jiang, J., et al. (2019) · Theranostics · doi:10.7150/thno.32126 · Cited by 99
Hexokinases in cancer and other pathologies
Guo, D. S., Meng, Y., Jiang, X., & Lu, Z. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100077 · Cited by 99
Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction
Rabaan, A. A., AlSaihati, H., Bukhamsin, R., Bakhrebah, M. A., Nassar, M. S., Alsaleh, A. A., Alhashem, Y. N., Bukhamseen, A. Y., Al-Ruhimy, K., Alotaibi, M. H., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020152 · Cited by 99
Gong, L., Wu, D., Zou, J., Chen, J., Chen, L.-Y., Chen, Y., Ni, C., & Yuan, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7607 · Cited by 98
Erba, H. P., Becker, P. S., Shami, P. J., Grunwald, M. R., Flesher, D. L., Zhu, M., Rasmussen, E., Henary, H. A., Anderson, A. A., & Wang, E. S. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019030916 · Cited by 98
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01317-9 · Cited by 98
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Mao, H., Zhang, L., Yang, Y., Zuo, W., Bi, Y., Gao, W., Deng, B., Sun, J., Shao, Q., & Qu, X. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793605811 · Cited by 97
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Sun, Y.-C., Hong, J. H., Ning, Z., Pan, D., Fu, X., Lu, X., & Tan, J. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932914 · Cited by 97
Barlaam, B. C., Cosulich, S. C., Degorce, S. L., Fitzek, M., Green, S. A., Hancox, U. J., der Brempt, C. L., Lohmann, J.-J. M., Maudet, M., Morgentin, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501629p · Cited by 95
Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
Burchett, K. M., Yan, Y., & Ouellette, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085155 · Cited by 95
Monaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S., Wang, H. Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2563 · Cited by 95
Wannhoff, A., Hov, J. R., Folseraas, T., Rupp, C., Friedrich, K., Anmarkrud, J. A., Weiss, K. H., Sauer, P., Schirmacher, P., Boberg, K. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.005 · Cited by 94
Deeraksa, A., Pan, J., Sha, Y., Liu, X.-D., Eissa, N. T., Lin, S.-H., & Yu-Lee, L.-Y. (2012) · Oncogene · doi:10.1038/onc.2012.309 · Cited by 94
Okamoto, I., Kaneda, H., Satoh, T., Okamoto, W., Miyazaki, M., Morinaga, R., Ueda, S., Terashima, M., Tsuya, A., Sarashina, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0379 · Cited by 94
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 94
Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics
Ancrile, B. B., O’Hayer, K., & Counter, C. M. (2008) · Molecular Interventions · doi:10.1124/mi.8.1.6 · Cited by 93
High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis
Qi, S.-A., Wu, Q., Chen, Z., Zhang, W., Zhou, Y., Mao, K., Li, J., Li, Y., Chen, J., Huang, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91276-2 · Cited by 93
Self-citationLi, M., Li, L., Zheng, J., Li, Z., Li, S., Wang, K., & Chen, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01745-7 · Cited by 93
Zhou, W.-H., Tang, F., Xu, J., Wu, X., Yang, S.-B., Feng, Z.-Y., Ding, Y.-G., Wan, X., Guan, Z., Li, H.-G., et al. (2012) · Autophagy · doi:10.4161/auto.18641 · Cited by 92
Self-citationZhang, J., Guan, M., Wang, Q., Zhang, J., Zhou, T., & Sun, X. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz040 · Cited by 92
Grünwald, V., Karch, A., Schuler, M. K., Schöffski, P., Kopp, H., Bauer, S., Kasper, B., Lindner, L. H., Chemnitz, J., Crysandt, M. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00714 · Cited by 92
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F.-E. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 92
NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis
Wu, D., Wu, P., Zhao, L., Huang, L., Zhang, Z., Zhao, S., & Huang, J. (2015) · Medicine · doi:10.1097/md.0000000000001687 · Cited by 91
Klymenko, Y., Kim, O., Loughran, E. A., Yang, J., Lombard, R., Alber, M., & Stack, M. S. (2017) · Oncogene · doi:10.1038/onc.2017.171 · Cited by 90
Sunitinib in the Treatment of Thyroid Cancer
Ferrari, S. M., Centanni, M., Virili, C., Miccoli, M., Ferrari, P., Ruffilli, I., Ragusa, F., Antonelli, A., & Fallahi, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006165942 · Cited by 90
Yan, W., Xu, H., Dai, J., Peng, J., Wang, W., Xia, L., & Zhou, F. (2018) · BioMed Research International · doi:10.1155/2018/1804086 · Cited by 90
Franier, B. D. L., & Thompson, M. E. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.03.041 · Cited by 90
Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas
Khan, T., Relitti, N., Brindisi, M., Magnano, S., Zisterer, D. M., Gemma, S., Butini, S., & Campiani, G. (2019) · Medicinal Research Reviews · doi:10.1002/med.21646 · Cited by 90
Stein, E. M., DeAngelo, D. J., Chromik, J., Chatterjee, M., Bauer, S., Lin, C.-C., Suarez, C., de Vos, F., Steeghs, N., Cassier, P. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1295 · Cited by 90
FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells
Zhang, L., Wang, H., Ding, K., & Xu, J. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.04.015 · Cited by 89
Self-citationNilsson, O., Johansson, C., Glimelius, B. L. G., Persson, B., Nørgaard‐Pedersen, B., Andrén‐Sandberg, Å., & Lindholm, L. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.44 · Cited by 89
The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism
Meng, Y., Xu, X. J., Luan, H., Li, L., Dai, W., Li, Z., & Bian, J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0052 · Cited by 89
HE4 as a Biomarker for Endometrial Cancer
Behrouzi, R., Barr, C. E., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13194764 · Cited by 89
Wu, D., Jia, C., Chen, J., Lin, Z., Ruan, D., Li, X., Lin, Q., Min‐Dong, Ma, X., Wan, X., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2531-7 · Cited by 88
Kawa, S., Oguchi, H., Kobayashi, T., Tokoo, M., Furuta, S., Kanai, M., & Homma, T. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.422 · Cited by 88
The effects of telomerase inhibition on prostate tumor‐initiating cells
Marian, C. O., Wright, W. E., & Shay, J. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25043 · Cited by 88
Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis
Bozec, D., Iuga, A. C., Roda, G., Dahan, S., & Yeretssian, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10135 · Cited by 88
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Sullivan, R. J., Hollebecque, A., Flaherty, K. T., Shapiro, G. I., Rodon, J. A., Millward, M., Zhang, W., Gao, L., Sykes, A. K., Willard, M. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0681 · Cited by 88
Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer
Yuan, Z.-Y., Luo, Li, M., Xi, S., Fu, J., & He (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46222 · Cited by 87
The Structural Biology of Bcl-xL
Lee, E. F., & Fairlie, W. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092234 · Cited by 87
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 87
Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
Demková, L., & Kučerová, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0795-z · Cited by 86
Interpreting raised serum ferritin levels
Koperdanova, M., & Cullis, J. (2015) · BMJ · doi:10.1136/bmj.h3692 · Cited by 85
Dietary interventions and precision nutrition in cancer therapy
Martínez-Garay, C., & Djouder, N. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.004 · Cited by 85
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 85
Serum ?-L-fucosidase activity and early detection of hepatocellular carcinoma
Giardina, M. G., Matarazzo, M., Morante, R., Lucariello, A., Varriale, A., Guardasole, V., & Marco, G. D. (1998) · Cancer · Cited by 84
Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
Pacchiana, G., Chiriaco, C., Stella, M. C., Petronzelli, F., Santis, R. D., Galluzzo, M., Carminati, P., Comoglio, P. M., Michieli, P., & Vigna, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134031 · Cited by 84
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01806-z · Cited by 84
ALK-rearrangements and testing methods in non-small cell lung cancer: a review
Shackelford, R. E., Vora, M., Mayhall, K., & Cotelingam, J. D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.3 · Cited by 83
Li, X., Guo, J., Ding, A., Qi, W., Zhang, P., Lv, J., Qiu, W., & Sun, Z. (2016) · Technology in Cancer Research & Treatment · doi:10.1177/1533034616655909 · Cited by 83
The RAS–Effector Interaction as a Drug Target
Keeton, A. B., Salter, E. A., & Piazza, G. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0938 · Cited by 83
Proteomics biomarkers for solid tumors: Current status and future prospects
Belczacka, I., Latosińska, A., Metzger, J., Marx, D., Vlahou, A., Mischak, H., & Frantzi, M. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21572 · Cited by 83
Buparlisib is a brain penetrable pan-PI3K inhibitor
de Gooijer, M. C., Zhang, P., Buil, L. C. M., Çitirikkaya, C. H., Thota, N., Beijnen, J. H., & van Tellingen, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-29062-w · Cited by 83
van Vlodrop, I. J. H., Baldewijns, M. M. L. L., Smits, K. M., Schouten, L. J., Neste, L. V., Criekinge, W. V., van Poppel, H., Lerut, E., Schuebel, K. E., Ahuja, N., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090442 · Cited by 82
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
Dias, J. R. D. O., de Andrade, G. C., Novais, E. A., Farah, M. E., & Rodrigues, E. B. (2016) · International Journal of Retina and Vitreous · doi:10.1186/s40942-016-0026-y · Cited by 82
Human TERT promoter mutations as a prognostic biomarker in glioma
Powter, B., Jeffreys, S. A., Sareen, H., Cooper, A. J., Brungs, D., Po, J. W., Roberts, T. L., Koh, E., Scott, K. F., Sajinovic, M., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03536-3 · Cited by 82
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation
Kansara, M., Leong, H. S., Lin, D., Popkiss, S., Pang, P., Garsed, D. W., Walkley, C. R., Cullinane, C. M., Ellul, J., Haynes, N. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70559 · Cited by 81
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Untch, B. R., Anjos, V. D., García-Rendueles, M. E. R., Knauf, J. A., Krishnamoorthy, G. P., Saqcena, M., Bhanot, U. K., Socci, N. D., Ho, A. L., Ghossein, R. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1925 · Cited by 81
Cancer Biomarker Discovery for Precision Medicine: New Progress
Zou, J., & Wang, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180718164712 · Cited by 81
Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy
Silva, V. R., Neves, S. P., Santos, L. D. S., Dias, R. B., & Bezerra, D. P. (2020) · Cancers · doi:10.3390/cancers12113461 · Cited by 81
He, Y., Zhao, X., Subahan, N. R., Fan, L., Gao, J., & Chen, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2060-4 · Cited by 80
Masuda, G., Yashiro, M., Kitayama, K., Miki, Y., Kasashima, H., Kinoshita, H., Morisaki, T., Fukuoka, T., Hasegawa, T., Sakurai, K., et al. (2016) · PubMed · Cited by 80
Ertao, Z., Jianhui, C., Wang, K., Ye, Z., Wu, H., Chuangqi, C., Changjiang, Q., Sile, C., Yulong, H., & Shirong, C. (2016) · Tumor Biology · doi:10.1007/s13277-016-5229-1 · Cited by 80
Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
Ayoub, W. S., Steggerda, J. A., Yang, J. D., Kuo, A., Sundaram, V., & Lu, S. C.-L. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919869120 · Cited by 80
Tang, J., Deng, R., Luo, R.-Z., Shen, G.-P., Cai, M.-Y., Du, Z.-M., Jiang, S., Yang, M.-T., Fu, J., & Zhu, X. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2080-y · Cited by 79
Molecular Electron Microscopy: State of the Art and Current Challenges
Stahlberg, H., & Walz, T. (2008) · ACS Chemical Biology · doi:10.1021/cb800037d · Cited by 79
p62 as a therapeutic target for tumor
Tao, M., Liu, T., You, Q., & Jiang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112231 · Cited by 79
Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)
Meng, D., He, W. A., Zhang, Y., Liang, Z., Zheng, J., Zhang, X., Zheng, X., Zhan, P., Chen, H., Li, W.-J., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105900 · Cited by 79
Self-citationRuan, J., Mei, L., Zhu, Q., Shi, G., & Wang, H. (2015) · PubMed · Cited by 78
Targeting telomerase for its advent in cancer therapeutics
Bajaj, S., Kumar, M. S., Peters, G. J., & Mayur, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21674 · Cited by 78
Rocca, A., Braga, L., Volpe, M. C., Maiocchi, S., & Generali, D. (2022) · Cancers · doi:10.3390/cancers14215306 · Cited by 78
Bertorelle, R., Briarava, M., Rampazzo, E., Biasini, L., Agostini, M., Maretto, I., Lonardi, S., Friso, M. L., Mescoli, C., Zagonel, V, et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.602 · Cited by 77
Maeda, G., Chiba, T., Okazaki, M., Satoh, T., Taya, Y., Aoba, T., Kato, K., Kawashiri, S., & Imai, K. (2005) · PubMed · Cited by 77
Effects of novel HDAC inhibitors on urothelial carcinoma cells
Kaletsch, A., Pinkerneil, M., Hoffmann, M. J., Vasudevan, A. A. J., Wang, C., Hansen, F. K., Wiek, C., Hanenberg, H., Gertzen, C. G. W., Gohlke, H., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0531-y · Cited by 77
Zhang, L., Zha, Z., Qu, W., Zhao, H., Yuan, J., Feng, Y., & Wu, B. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4773-z · Cited by 77
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症:英文版 · doi:10.1002/cac2.12366 · Cited by 77
Zhang, Y., Zhang, J., Lin, Y., Lan, Y., Lin, C., Xuan, J. W., Shen, M. M., McKeehan, W. L., Greenberg, N. M., & Wang, F. (2008) · Development · doi:10.1242/dev.009910 · Cited by 76
Self-citationNordby, Y., Richardsen, E. H., Rakaee, M., Ness, N., Dønnem, T., Patel, H., Busund, L., Bremnes, R. M., & Andersen, S. (2017) · Scientific Reports · doi:10.1038/srep43378 · Cited by 76
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
Miranda, O., Farooqui, M., & Siegfried, J. M. (2018) · Cancers · doi:10.3390/cancers10090280 · Cited by 76
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
Lee, J. M., Kim, B., Lee, S. B., Jeong, Y., Oh, Y. M., Song, Y.-J., Jung, S. H., Choi, J., Lee, S., Cheong, K. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.551 · Cited by 75
Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma
Wang, W., Wen, Q., Xu, L., Xie, G., Li, J., Luo, J., Chu, S., Shi, L., Huang, D., Li, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106098 · Cited by 75
Dhillon, S., & Keam, S. J. (2021) · Drugs · doi:10.1007/s40265-021-01504-2 · Cited by 75
Recent Progress in Biosensors for Detection of Tumor Biomarkers
Li, M., Jiang, F., Xue, L., Peng, C. Y., Shi, Z., Zhang, Z., Li, J., Pan, Y., Wang, X., Feng, C., et al. (2022) · Molecules · doi:10.3390/molecules27217327 · Cited by 75
Kuo, S.-Y., Castoreno, A. B., Aldrich, L. N., Lassen, K. G., Goel, G., Dančík, V., Kuballa, P., Latorre, I. J., Conway, K. L., Sarkar, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512289112 · Cited by 74
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Terada, N., Akamatsu, S., Kobayashi, T., Inoue, T., Ogawa, O., & Antonarakis, E. S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719215 · Cited by 74
Zhang, B., Xie, Z., & Li, B. (2018) · Gene · doi:10.1016/j.gene.2018.12.006 · Cited by 74
Phenotyping Reveals Targets of a Pseudo‐Natural‐Product Autophagy Inhibitor
Foley, D. J., Zinken, S., Corkery, D., Laraia, L., Pahl, A., Wu, Y., & Waldmann, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202000364 · Cited by 74
Weiss, J., Yaeger, R. D., Johnson, M. L., Spira, A., Klempner, S. J., Barve, M. A., Christensen, J. G., Chi, A., Der-Torossian, H., Velastegui, K., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2093 · Cited by 73
Deletion of the E-cadherin gene in hepatitis B virus-positive chinese hepatocellular carcinomas
Slagle, B. L., Zhou, Y.-Z., Birchmeier, W., & Scorsone, K. A. (1993) · Hepatology · doi:10.1002/hep.1840180402 · Cited by 73
Self-citationXian, W., Pappas, L., Pandya, D., Selfors, L. M., Derksen, P. W. B., de Bruin, M., Gray, N. S., Jonkers, J., Rosen, J. M., & Brugge, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3398 · Cited by 73
Gana‐Weisz, M., Halaschek-Wiener, J., Jansen, B., Elad, G., Haklai, R., & Kloog, Y. (2002) · PubMed · Cited by 72
Sunitinib in the treatment of metastatic renal cell carcinoma
Schmid, T. A., & Gore, M. E. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287216663979 · Cited by 72
Emerging biomarkers in Multiple Myeloma: A review
Gupta, N., Sharma, A., & Sharma, A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.026 · Cited by 72
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.